As shown in Figure 1, accessibility losses at RFX/IRF/STAT-bearing regulatory elements near HLA-A/B/C, TAP1, and PSMB8/9, together with diminished NLRC5 enhancer activity, are recurrent features in immune-cold tumor regions and correspond to reduced interferon-response competence, consistent with prior single-cell and bulk chromatin studies in solid tumors (44, 45). Here, TRIM63 is linked to neoplasm.